Kissei Pharmaceutical (TYO:4547) has signed a sub-licensing deal with Tai Tien Pharmaceuticals for the development and commercialization of Tavalisse (fostamatinib disodium hexahydrate) in Taiwan, according to a Tuesday filing on the Tokyo Stock Exchange.
Tai Tien will receive commercialization rights, while Kissei will supply the product and receive upfront and milestone payments.
The oral SYK inhibitor, approved in multiple regions, treats chronic idiopathic thrombocytopenic purpura (ITP).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments